Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1031783 | 1.00 | KDM4E (0.60) | KDM4EL3MBTL1GAAALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL2673610 | 0.97 | KDM4E (0.58) | KDM4EL3MBTL1GAAALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL7527100 | 0.97 | KDM4E (0.58) | KDM4EL3MBTL1GAAALDH1A1POLB | |
| SCHEMBL168399 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL73679 | 0.95 | KDM4E (0.60) | KDM4EL3MBTL1GAAALDH1A1POLB | |
| Bromide SCHEMBL5245144 | 0.95 | KDM4E (0.60) | KDM4EL3MBTL1GAAALDH1A1POLB | |
| SCHEMBL1259867 | 0.92 | — | — | |
| SCHEMBL23014621 | 0.90 | KDM4E (0.60) | KDM4EL3MBTL1GAAALDH1A1POLB | |
| SCHEMBL7748218 | 0.90 | KDM4E (0.60) | KDM4EL3MBTL1GAAALDH1A1POLB | |
| SCHEMBL6174155 | 0.88 | KDM4E (0.59) | KDM4EL3MBTL1GAAALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 827 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119798223-A | (1H-indazol-5-yl) amino-2-pyridine derivative and application thereof | 沈阳药科大学 | 2025-04-11 | — | — | CN | claimed |
| CN-115246842-B | Small molecule inhibitors targeting deubiquitinase USP25 and USP28 | 深圳湾实验室 | 2024-05-24 | — | — | CN | claimed |
| CN-115246842-A | Small molecule inhibitors targeting deubiquitinases USP25 and USP28 | 深圳湾实验室 | 2022-10-28 | — | — | CN | claimed |
| CN-114728009-A | Preventing or treating diseases and disorders associated with tissue damage | 李晓祥 | 2022-07-08 | — | — | CN | claimed |
| US-20210038589-A1 | USES, COMPOSITIONS AND METHODS | FISAHN ANDRE (SE) | 2021-02-11 | — | — | US | claimed |
| EP-3765082-A1 | USES, COMPOSITIONS AND METHODS | Fisahn, André (SE) | 2021-01-20 | — | — | EP | claimed |
| EP-3290420-B1 | PYRIMIDINE PYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | UNIV XIAMEN (CN) | 2020-12-09 | — | — | EP | claimed |
| US-20200207779-A2 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2020-07-02 | — | — | US | claimed |
| WO-2019175395-A1 | USES, COMPOSITIONS AND METHODS | FISAHN ANDRE (SE) | 2019-09-19 | — | — | WO | claimed |
| US-20190211030-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2019-07-11 | — | — | US | claimed |
| US-5733956-A | COMPRISES A THERMOPLASTIC OLEFIN, A MONOMERIC AND A POLYMERIC HINDERED AMINE LIGHT STABILIZER AND AN ULTRAVIOLET LIGHT ABSORBING BENZOTRIAZOLE | SOLVAY ENGINEERED POLYMERS (US) | 1998-03-31 | — | — | US | claimed |
| EP-0434943-B1 | Polyene macrolide derivatives | PRODOTTI ANTIBIOTICI SPA (IT) | 1995-09-06 | — | — | EP | claimed |
| WO-1994024095-A1 | IMMUNOSUPPRESSIVE AGENTS | ABBOTT LABORATORIES (US) | 1994-10-27 | — | — | WO | claimed |
| US-5296597-A | Antibiotics | SPA SOCIETA' PRODOTTI ANTIBIOTICI S.P.A. (IT) | 1994-03-22 | — | — | US | claimed |
| EP-0434943-A1 | Polyene macrolide derivatives | S P A SOCIETA' PRODOTTI ANTIBIOTICI S.p.a. (IT) | 1991-07-03 | — | — | EP | claimed |
| EP-0178947-B1 | 1-[(Aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-alpha,alpha-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles | A.H. ROBINS COMPANY, INCORPORATED (US) | 1990-09-26 | — | — | EP | claimed |
| US-4791199-A | Process for antiarrhythmic 1,3-diazabicyclo[4.4.0]dec-2-en-4-ones | G. D. SEARLE & CO. (US) | 1988-12-13 | — | — | US | claimed |
| EP-0234331-A1 | Octahydropyrido[1,2-c]-pyrimidinones | G.D. Searle & Co. (US) | 1987-09-02 | — | — | EP | claimed |
| EP-0215477-A1 | Process and intermediates for antiarrhytmic 1,3-diazabicyclo/4.4.0/dec-2-en-4-ones | G.D. Searle & Co. (US) | 1987-03-25 | — | — | EP | claimed |
| US-4122265-A | APPETITE SUPPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1978-10-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210038589-A1 | USES, COMPOSITIONS AND METHODS | APP, CACNA1G, CACNA1B | KDM4E 4234/4885L3MBTL1 4840/4885GAA 278/4885 |
| US-20190211030-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ALK, MET, TIE1 | KDM4E 463/4885L3MBTL1 1569/4885GAA 2871/4885 |
| US-20200207779-A2 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ALK, MET, TIE1 | KDM4E 463/4885L3MBTL1 1569/4885GAA 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.